Centene Corp (CNC) · Sep 15, 2026 · Guidance

Centene reaffirms 2026 EPS guidance, offering investors no new catalyst

Guidance reaffirmed — GAAP EPS >$3.11; adjusted EPS >$4.80

Centene repeats its 2026 EPS floors at an investor conference, confirming the recovery plan but adding no new financial information.

Centene is in a profitability-recovery phase after severe Marketplace and Medicaid pressure, using better pricing, risk-adjustment revenue, Medicaid rate actions and Medicare PDP growth to rebuild earnings power. Its second-quarter update had already lifted 2026 adjusted EPS guidance above $4.80, while acknowledging that roughly $0.50 of the improvement came from non-recurring Medicare and Commercial items.

This filing adds confirmation, not information. Management is simply repeating the existing full-year floors: The same adjusted EPS guidance had already been reaffirmed publicly on August 17, 2026.

MeasureReaffirmed 2026 guidance
GAAP diluted EPS>$3.11
Adjusted diluted EPS>$4.80

The recovery plan remains intact, but this is not another upgrade. The filing provides no new operating metrics, no new earnings data and no additional detail on whether medical-cost trends or membership are tracking better than the July outlook. It therefore does not materially change the standing business story.

Bottom line: Centene is holding its recovery targets, but this 8-K is a scheduled investor-relations confirmation rather than a fresh business development. Under the event-driven lens, it is neutral and already known.alk

What to watch next

Healthcare Summit presentation, September 16

Original filing on SEC EDGAR

More Centene Corp news

Centene reaffirms 2026 EPS guidance, offering investors no new catalyst | CNC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.